{"id":620,"date":"2021-06-07T09:05:11","date_gmt":"2021-06-07T09:05:11","guid":{"rendered":"http:\/\/events.marketsandmarkets.com\/blog\/?p=620"},"modified":"2021-06-07T09:05:11","modified_gmt":"2021-06-07T09:05:11","slug":"tumor-targeted-costimulatory-trimerbodies-for-cancer-immunotherapy-a-brief-discussion-with-juan-perez-villar-ceo-leadartis","status":"publish","type":"post","link":"https:\/\/events.marketsandmarkets.com\/blognew\/tumor-targeted-costimulatory-trimerbodies-for-cancer-immunotherapy-a-brief-discussion-with-juan-perez-villar-ceo-leadartis\/","title":{"rendered":"\u201cTumor-targeted costimulatory trimerbodies for cancer immunotherapy.\u201d- A brief discussion with Juan Perez Villar, CEO, LeadArtis."},"content":{"rendered":"\n

Doctor in Immunology from the Autonomous University\nof Madrid (Spain), extensive international career in the biopharmaceutical\nindustry at Astellas Inc. and Bristol-Myers Squibb Co. (USA). Experienced\nR&D leader in immune-oncology (IO). Previously, participated in preclinical\ndevelopment of CD28 biologic modulators for inflammatory conditions, small\nmolecule tyrosine kinase inhibitors and fully human antibodies for advanced\nsolid tumors at Leadartis. He advanced the company from start to capitalize on\nthe immuno-oncology (IO) market. Evaluated and repositioned the platform\ntechnology to create IO bispecific antibody dominance and created a proprietary\nnext generation product pipeline for clinical development<\/p>\n\n\n\n

Marketsandmarkets talked with Juan about his upcoming presentation and his newfound developments in the arenas of Immuno-oncology. Their own research and learnings in the field and organization & their take on the conference program.\u00a0\u00a0 <\/p>\n\n\n\n

Question: <\/strong>What\nare the recent advances in the immune-oncology and current challenges that need\nimmediate attention?<\/strong><\/p>\n\n\n\n

Juan Perez:<\/strong><\/strong><\/p>\n\n\n\n

A variety of BsAb formats have been generated.\nAccording to the structure of Fc domain, BsAb can be classified into two types:\nIgG-like format and Fc-free format. BsAb has achieved an exciting breakthrough\nin hematological malignancies but limited outcome in solid tumor as showed in\nvarious clinical trials. We need to generate new non toxic configurations that\novercome this limitations.<\/p>\n\n\n\n

Question: <\/strong>What\nis the key take away point from your presentation topic which will help in\nbuilding the knowledge base of attendees? \n<\/strong><\/p>\n\n\n\n

Juan Perez:<\/strong><\/strong><\/p>\n\n\n\n

Bispecific\nHexavalent Trimerbodies (BHTs) are multi-valent bispecific costimulatory tumor\ntargeted antibodies directed against two clinically validated targets, on\neffector T lymphocytes and other tumor specific. Preclinical results exhibit in\nvivo tumor regression + generation of long-lasting anti-tumor immune memory and\nsynergy with PD-1 (-L1) blockers. Contrary to conventional mAbs, BHTs are\nnon-toxic (i.e. devoid of systemic inflammation and hepatotoxicity or\nsplenomegaly) and present appropriate pharmacological properties.<\/p>\n\n\n\n

Juan Perez Villar, is our esteemed speaker\nat  4th Annual MarketsandMarkets Next Gen\nImmuno-Oncology Virtual Congress-US Edition<\/a> to be held on 28th- 01 July, 2021.. He will\nbe presenting on the Day 1 of the conference on the topic \u2013 \u2018Tumor-targeted\ncostimulatory trimerbodies for cancer immunotherapy<\/strong>.\u2019<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

To\nKnow more about the presentation, visit our website \u2013 https:\/\/bit.ly\/2PKXNvN<\/a> <\/p>\n\n\n\n

If\nyou wish to learn a great deal from him about the IO Research and drug\ndevelopment in cancer, then register\nonline<\/a> or email aradhna.robert@marketsandmarkets.com<\/a> to\nbook your slot at the conference.<\/p>\n","protected":false},"excerpt":{"rendered":"

Doctor in Immunology from the Autonomous University of Madrid (Spain), extensive international career in the biopharmaceutical industry at Astellas Inc. and Bristol-Myers Squibb Co. (USA). Experienced R&D leader in immune-oncology (IO). Previously, participated in preclinical development of CD28 biologic modulators for inflammatory conditions, small molecule tyrosine kinase inhibitors and fully human antibodies for advanced solid […]<\/p>\n","protected":false},"author":2,"featured_media":622,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_mi_skip_tracking":false},"categories":[3,2],"tags":[179,146,171,145,16,173],"_links":{"self":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/620"}],"collection":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/comments?post=620"}],"version-history":[{"count":1,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/620\/revisions"}],"predecessor-version":[{"id":623,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/620\/revisions\/623"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media\/622"}],"wp:attachment":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media?parent=620"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/categories?post=620"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/tags?post=620"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}